Since the development of the first vaccine more than 200 years ago, vaccination against viruses and bacteria has become a golden standard in medicine, which prevented some of the 20th century’s deadliest diseases with many lives saved.
Unlike traditional vaccines, Therapeutic Cancer Vaccines are a form of immunotherapy that can help “educate” the immune system to fight the body’s own malignant cells — various forms of tumors.
The idea of applying a vaccination principle to fight cancer is appealing, but cancer treatment is a substantially more challenging task compared to dealing with infectious diseases. First, cancer cells are the body’s own cells, so they are much “cleverer” in deceiving the immune system. Second, each tumor is in some way unique, with a unique set of antigens, and a unique biological context. This, and other reasons, all make the development of therapeutic cancer vaccines a gargantuan quest, and we are just starting to usher into a new era of truly effective personalized immunotherapy. However, the progress in the area is fast-paced, and the rewards are enormous — both for businesses and for patients.
During this 1-day event, November 23, we will share our findings from a unique market study revealing R&D platforms for developing therapeutic cancer vaccines, the key players in each category, the science behind the development, and case studies illustrating opportunities and challenges of each research strategy.
We will present our categorization of the 5 platforms — including relatively mainstream strategies — Neoantigen Platform, Tumor-associated Antigens Platform, Cellular Platform, and Oncolytic Viruses Platform — and the latest breakthrough and a potentially disruptive research strategy — Antigenic Essence Platform.
The webinar will host research and business presentations from the Deep Pharma Intelligence team and guest speaker presentations by invited industry experts.